Talarozole
Based on 22 publication(s) in Google Scholar
Talarozole (R115866) is an oral systemic all-trans retinoic acid metabolism blocking agent (RAMBA) which increases intracellular levels of endogenous all-trans retinoic acid (RA). Talarozole inhibits both CYP26A1 and CYP26B1 with IC50s of 5.4 and 0.46 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 201410-53-9
- Formula: C21H23N5S
- Molecular Weight:377.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Clinical Compound Library
HY-L026
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Mitochondria-Targeted Compound Library
HY-L089
-
Transcription Factor-Targeted Library
HY-L090
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Human Metabolite Library
HY-L123
-
Nuclear Receptor Compound Library
HY-L126
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Talarozole
More- Cell Stem Cell. 2025 Sep 4;32(9):1421-1437.e6. [Abstract]
- Dev Cell. 2018 Dec 17;47(6):711-726.e5. [Abstract]
- Clin Transl Med. 2023 Nov;13(11):e1465. [Abstract]
- Neurosci Bull. 2024 Mar;40(3):293-309. [Abstract]
- J Enzyme Inhib Med Chem. 2016;31(sup2):148-161. [Abstract]
- Toxicology. 2024 Aug 7:153907. [Abstract]
- Tissue Eng Regen Med. 2023 Aug;20(5):705-723. [Abstract]
- J Cell Physiol. 2018 Feb;233(2):1129-1145. [Abstract]
- J Biol Chem. 2026 Jan 29;302(3):111211. [Abstract]
- PLoS Genet. 2017 Dec 11;13(12):e1007112. [Abstract]
- Development. 2019 May 13;146(12). pii: dev173088. [Abstract]
- Toxicol Appl Pharmacol. 2024 May:486:116945. [Abstract]
- Biol Reprod. 2023 May 10;108(5):822-836. [Abstract]
- Mol Pharmacol. 2018 May;93(5):489-503. [Abstract]
- Mol Pharmacol. 2016 May;89(5):560-74. [Abstract]
- Mol Pharmacol. 2015;87(3):430-41. [Abstract]
- J Cell Biochem. 2021 Oct;122(10):1302-1312. [Abstract]
- J Exp Zool B Mol Dev Evol. 2017 Sep;328(6):575-586. [Abstract]
- University of Oxford. 2023 Oct.
- Mech Dev. 2020 Dec;164:103644. [Abstract]
- University of Texas. August 2017.
- Université Nice Sophia Antipolis. 5 Oct 2016.
Customer Validation & Images
-
IF
-
RT-PCR
-
IF
-
RT-PCR
Biological Activity
|
CYP26 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
0.0051 μM
Compound: 3; R115866
|
Inhibition of microsomal fraction of human CYP26A1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 1 min by HPLC analysis in presence of rat P450 reductase
Inhibition of microsomal fraction of human CYP26A1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 1 min by HPLC analysis in presence of rat P450 reductase
|
[PMID: 26918322] |
| Sf9 | IC50 |
0.00046 μM
Compound: 3; R115866
|
Inhibition of microsomal fraction of human CYP26B1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by HPLC analysis in presence of rat P450 reductase
Inhibition of microsomal fraction of human CYP26B1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by HPLC analysis in presence of rat P450 reductase
|
[PMID: 26918322] |
| Sf9 | IC50 |
0.46 nM
Compound: 3; R115866
|
Inhibition of microsomal fraction of human CYP26B1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by HPLC analysis in presence of rat P450 reductase
Inhibition of microsomal fraction of human CYP26B1 expressed in Sf9 cells using 9-cis-RA as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by HPLC analysis in presence of rat P450 reductase
|
[PMID: 26918322] |
When HepG2 cells are cotreated with atRA and Talarozole (1 μM), 4-OH-RA and 4-oxo-RA formation is significantly decreased[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 201410-53-9
-
Appearance Solid
-
Molecular Weight 377.51
-
Formula C21H23N5S
-
Color White to off-white
-
SMILES
CCC(CC)C(C1=CC=C(NC2=NC3=CC=CC=C3S2)C=C1)N4N=CN=C4
-
Synonyms
R115866
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Cell Stem Cell
Multi-omic analysis reveals retinoic acid molecular drivers for dermal fibrosis and regenerative repair in the skin. [Abstract]2025 Sep 4;32(9):1421-1437.e6. PMID: 40816279 -
Dev Cell
2018 Dec 17;47(6):711-726.e5. PMID: 30449506 -
Clin Transl Med
Metformin reduces hepatocarcinogenesis by inducing downregulation of Cyp26a1 and CD8+ T cells. [Abstract]2023 Nov;13(11):e1465. PMID: 37997519 -
Neurosci Bull
2024 Mar;40(3):293-309. PMID: 37639183 -
J Enzyme Inhib Med Chem
Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases. [Abstract]2016;31(sup2):148-161. PMID: 27424662 -
Toxicology
Exosomes-mediated retinoic acid disruption: A link between gut microbiota depletion and impaired spermatogenesis. [Abstract]2024 Aug 7:153907. PMID: 39121937 -
Tissue Eng Regen Med
Wnt/β-Catenin Promotes the Osteoblastic Potential of BMP9 Through Down-Regulating Cyp26b1 in Mesenchymal Stem Cells. [Abstract]2023 Aug;20(5):705-723. PMID: 37010733 -
J Cell Physiol
WNT4 acts downstream of BMP2 to mediate the regulation of ATRA signaling on RUNX1 expression: Implications for terminal differentiation of antler chondrocytes. [Abstract]2018 Feb;233(2):1129-1145. PMID: 28436029 -
J Biol Chem
A cell-based assay for retinaldehyde dehydrogenase activity: Retinoid quantification as an alternative to current fluorescence-based approaches. [Abstract]2026 Jan 29;302(3):111211. PMID: 41617028 -
PLoS Genet
In vivo zebrafish morphogenesis shows Cyp26b1 promotes tendon condensation and musculoskeletal patterning in the embryonic jaw. [Abstract]2017 Dec 11;13(12):e1007112. PMID: 29227993
Talarozole purchased from MedChemExpress. Usage Cited in: PLoS Genet. 2017 Dec 11;13(12):e1007112. [Abstract]
Embryos raised in media containing 0.01% DMSO develop normally. 100% of embryos treated with Talarozole between 54 and 60 hpf displayed ectopic muscle projection in the second pharyngeal arch, and the intermandibularis posterior muscles overextended in 58.3% of embryos (n=64).
-
Development
Differential RA responsiveness directs formation of functionally distinct spermatogonial populations at the initiation of spermatogenesis in the mouse. [Abstract]2019 May 13;146(12). pii: dev173088. PMID: 31023878 -
Toxicol Appl Pharmacol
In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1. [Abstract]2024 May:486:116945. PMID: 38688424 -
Biol Reprod
Differential responsiveness of spermatogonia to retinoic acid dictates precocious differentiation but not meiotic entry during steady-state spermatogenesis. [Abstract]2023 May 10;108(5):822-836. PMID: 36708226 -
Mol Pharmacol
CYP26C1 Is a Hydroxylase of Multiple Active Retinoids and Interacts with Cellular Retinoic Acid Binding Proteins. [Abstract]2018 May;93(5):489-503. PMID: 29476041 -
Mol Pharmacol
2016 May;89(5):560-74. PMID: 26921399
Talarozole purchased from MedChemExpress. Usage Cited in: Mol Pharmacol. 2016 May;89(5):560-74. [Abstract]
Induction of hepatic mitochondrial biogenesis genes in mice after Talarozole (TLZ) treatment compared with vehicle-treated mice. All mRNA data are presented as fold change in mRNA abundance relative to control mice. β-Actin is used as the housekeeping gene. For protein data, results are expressed as ratio of SDHA to β-actin.
-
Mol Pharmacol
Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids. [Abstract]2015;87(3):430-41. PMID: 25492813 -
J Cell Biochem
A novel lncRNA LOLA1 may predict malignant progression and promote migration, invasion, and EMT of oral leukoplakia via the AKT/GSK-3β pathway. [Abstract]2021 Oct;122(10):1302-1312. PMID: 33969929 -
J Exp Zool B Mol Dev Evol
ATRA Signaling Regulates the Expression of COL9A1 through BMP2-WNT4-RUNX1 Pathway in Antler Chondrocytes. [Abstract]2017 Sep;328(6):575-586. PMID: 28643469
Talarozole purchased from MedChemExpress. Usage Cited in: J Exp Zool B Mol Dev Evol. 2017 Sep;328(6):575-586. [Abstract]
Effect of R115866 on COL9A1 expression. R115866 enhances the effect of ATRA on COL9A1 expression. R115866 (1 μM) is dissolved in DMSO. Control receive the vehicle only.
-
-
Mech Dev
The Cdx transcription factors and retinoic acid play parallel roles in antero-posterior position of the pectoral fin field during gastrulation. [Abstract]2020 Dec;164:103644. PMID: 32911082 -
Talarozole purchased from MedChemExpress. Usage Cited in: University of Texas. August 2017.
100% of embryos treated with Talarozole between 54 and 60 hpf displayed ectopic muscle projection in the second pharyngeal arch, and the intermandibularis posterior muscles overextended in 58.3% of embryos (n = 64).
-
Solvent & Solubility
DMSO : 33.33 mg/mL (88.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (5.30 mM); Suspended solution
This protocol yields a suspended solution of ≥ 2 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Human liver microsomes (0.2 mg/mL) are incubated with 4-OH-atRA (500 nM) and NADPH, NADP+ or NAD+ (each at 2 mM) in 100 mM KPi buffer pH 7.4. In addition, 4-OH-atRA is incubated with human liver microsomes in the presence and absence of Talarozole (1 μM), a CYP26A1 specific inhibitor, and Ketoconazole (10 μM) a pan-P450 inhibitor and with NADPH as a cofactor. Following a 5 min pre-incubation, the reactions are initiated with the addition of cofactor and incubated for 30 minutes. At 30 min the reactions are quenched with equal volume of Acetonitrile and centrifuged at 3,000 g for 15 min. The supernatants are collected and 4-oxo-atRA formation is analyzed by LC-MS/MS. All incubations are normalized to a no cofactor control[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[3]
Talarozole is administered to mice as a single dose (2.5 mg/kg) or as multiple doses for three days. Serum Talarozole concentrations and serum, liver and testes atRA concentrations are measured by LC-MS/MS. Inhibition of CYP26 and changes inatRA concentrations in each tissue are predicted based on CYP26 activity in vitro and Talarozole disposition. Markers of fatty acid oxidation in the liver and spermatogonial differentiation in the testes are measured following Talarozole treatment.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Diaz P, et al. Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, theHuman Liver Retinoic Acid Hydroxylase. J Med Chem. 2016 Mar 24;59(6):2579-95. [Content Brief]
[2]. Topletz AR, et al. Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in theelimination of active retinoids. Mol Pharmacol. 2015;87(3):430-41. [Content Brief]
[4]. Tripathy S, et al.All-Trans-Retinoic Acid Enhances Mitochondrial Function in Models of Human Liver. Mol Pharmacol. 2016 May;89(5):560-74. [Content Brief]
[5]. Bovenschen HJ, et al. Oral retinoic acid metabolism blocking agent Rambazole for plaque psoriasis: an immunohistochemical study. Br J Dermatol. 2007 Feb;156(2):263-70. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6489 mL | 13.2447 mL | 26.4894 mL | 66.2234 mL |
| 5 mM | 0.5298 mL | 2.6489 mL | 5.2979 mL | 13.2447 mL | |
| 10 mM | 0.2649 mL | 1.3245 mL | 2.6489 mL | 6.6223 mL | |
| 15 mM | 0.1766 mL | 0.8830 mL | 1.7660 mL | 4.4149 mL | |
| 20 mM | 0.1324 mL | 0.6622 mL | 1.3245 mL | 3.3112 mL | |
| 25 mM | 0.1060 mL | 0.5298 mL | 1.0596 mL | 2.6489 mL | |
| 30 mM | 0.0883 mL | 0.4415 mL | 0.8830 mL | 2.2074 mL | |
| 40 mM | 0.0662 mL | 0.3311 mL | 0.6622 mL | 1.6556 mL | |
| 50 mM | 0.0530 mL | 0.2649 mL | 0.5298 mL | 1.3245 mL | |
| 60 mM | 0.0441 mL | 0.2207 mL | 0.4415 mL | 1.1037 mL | |
| 80 mM | 0.0331 mL | 0.1656 mL | 0.3311 mL | 0.8278 mL |
Powered by Bioz